Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 346 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetic Retinopathy
Interventions
BI 765128, Sham comparator
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more
Conditions
Diabetes, Macular Edema, Diabetic Retinopathy, Retinal Disease, Uveitis, Posterior
Interventions
DEX PS DDS®
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Sunnyvale, California
Conditions
Diabetic Retinopathy
Interventions
I-SITE Intervention, Usual Care Teleophthalmology
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Diabetes Mellitus
Interventions
Diabetes Mobile Application
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion (RVO)
Interventions
Iheezo, Lidocaine pledget
Drug
Lead sponsor
Retina Consultants of Delmarva
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Easton, Maryland
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging

NCT00556114
Conditions
Glaucoma, Diabetic Retinopathy, Age-Related Macular Degeneration, Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
Optical Coherence Tomography
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Irvine, California
Conditions
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
bevacizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Macular Edema, Diabetes Mellitus
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetic Retinopathy
Interventions
Aflibercept, Sham
Drug
Lead sponsor
Rishi Singh
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Conditions
Diabetic Retinopathy
Interventions
ruboxistaurin, placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
36
States / cities
Artesia, California • Palm Springs, California • Poway, California + 33 more
Conditions
Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
Interventions
Anterior Chamber (AC) Tap
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetes Mellitus, Macular Edema
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
Completed Not applicable Interventional Results available

ACCESS: AI for pediatriC diabetiC Eye examS Study

NCT05131451
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Point of Care Autonomous AI diabetic retinopathy exam
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
aflibercept
Drug
Lead sponsor
Rishi Singh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Center-involved Diabetic Macular Edema (CI-DME)
Interventions
Diabetes Visual Function Study (DiVFuSS) softgels, canola oil placebo softgels, 2 per day
Dietary Supplement · Other
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Olympia, Washington • Tacoma, Washington
Conditions
Diabetic Retinopathy
Interventions
PAN-90806 Ophthalmic Solution
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Harlingen, Texas • McAllen, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

NCT03403699
Conditions
Diabetes Complications, Diabetic Retinopathy
Interventions
Generation of inducible pluripotent stem cells
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 98 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Age Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions
Text Message Reminder, Health Worker Visit
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Diabetic Macular Edema
Interventions
Octreotide (drug), Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia
Interventions
Ozurdex Drug Implant Product
Drug
Lead sponsor
Retina Macula Specialists of Miami, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
North Miami Beach, Florida • South Miami, Florida
Completed Phase 2 Interventional Accepts healthy volunteers

Retinal Blood Flow and Microthrombi in Type 1 Diabetes

NCT00406991
Conditions
Diabetes, Diabetic Retinopathy
Interventions
aspirin, clopidogrel
Drug
Lead sponsor
Schepens Eye Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts